67
Participants
Start Date
September 7, 2017
Primary Completion Date
June 25, 2022
Study Completion Date
June 25, 2022
ONCOS-102
ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
Durvalumab
Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
Cyclophosphamide
A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
Research Facility, New York
Research Facility, Buffalo
Research Facility, Charlottesville
Research Facility, Miami
Research Facility, Toledo
Research Facility, San Diego
Lead Sponsor
Collaborators (1)
Cancer Research Institute, New York City
OTHER
MedImmune LLC
INDUSTRY
Targovax ASA
INDUSTRY
Ludwig Institute for Cancer Research
OTHER